Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-Label (Formerly Double-Blind), Phase 2 Trial to Assess Safety and Efficacy of Lenvatinib at Two Different Starting Doses (18 mg vs. 14 mg QD) in Combination With Everolimus (5 mg QD) in Renal Cell Carcinoma Following One Prior VEGF-Targeted Treatment

NCT03173560 is registered in ClinicalTrials.gov with Eisai Inc. as lead sponsor.

NCT NCT03173560
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03173560 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-Label (Formerly Double-Blind), Phase 2 Trial to Assess Safety and Efficacy of Lenvatinib at Two Different Starting Doses (18 mg vs. 14 mg QD) in Combination With Everolimus (5 mg QD) in Renal Cell Carcinoma Following One Prior VEGF-Targeted Treatment
Lead sponsor
Eisai Inc.
Phase
Phase 2
Overall status
Completed
Start date
August 17, 2017
Completion date
June 20, 2024
Enrollment
343 (actual)
Sites
93

Conditions

As the registry lists them; a condition with its own page is linked.

renal cell carcinoma